Lupin Secures US FDA Approval for Dapagliflozin Tablets

Lupin Limited has announced that it has received approval from the US FDA for its Dapagliflozin Tablets, marking a key milestone in expanding its diabetes portfolio in the United States. The approved product is a generic version of the widely used SGLT2 inhibitor, originally marketed as Farxiga.

Strengthening Diabetes Portfolio in a High-Growth Market

The approval enhances Lupin’s presence in the rapidly growing US antidiabetic therapeutics market, particularly in SGLT2 inhibitors, which are increasingly prescribed for type 2 diabetes, heart failure, and chronic kidney disease. This development is expected to support Lupin’s strategy of expanding its complex generics portfolio.

Expanding Access to Cost-Effective Cardiometabolic Therapies

With multiple indications and rising global demand for SGLT2 inhibitors, the entry of a generic version is likely to improve patient access and affordability. It also reinforces the competitive dynamics in the US generics space, where manufacturers are focusing on high-value chronic disease segments.